Literature DB >> 29235068

Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Jonathan Jia Yuan Ong1,2,3, Milena De Felice4.   

Abstract

Migraine is a common and disabling primary headache disorder with a significant socioeconomic burden. The management of migraine is multifaceted and is generally dichotomized into acute and preventive strategies, with several treatment modalities. The aims of acute pharmacological treatment are to rapidly restore function with minimal recurrence, with the avoidance of side effects. The choice of pharmacological treatment is individualized, and is based on the consideration of the characteristics of the migraine attack, the patient's concomitant medical problems, and treatment preferences. Notwithstanding, a good understanding of the pharmacodynamic and pharmacokinetic properties of the various drug options is essential to guide therapy. The current approach and concepts relevant to the acute pharmacological treatment of migraine will be explored in this review.

Entities:  

Keywords:  Migraine acute treatment; Pharmacology; Therapeutics

Mesh:

Substances:

Year:  2018        PMID: 29235068      PMCID: PMC5935632          DOI: 10.1007/s13311-017-0592-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  144 in total

1.  Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors.

Authors:  P De Vries; C M Villalón; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

2.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

3.  The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.

Authors:  Randolph W Evans; Stewart J Tepper; Robert E Shapiro; Christina Sun-Edelstein; Gretchen E Tietjen
Journal:  Headache       Date:  2010-06       Impact factor: 5.887

4.  Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.

Authors:  E Müller-Schweinitzer
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

5.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

Authors:  R B Lipton; W F Stewart; A M Stone; M J Láinez; J P Sawyer
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

Review 6.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Authors:  David Dodick; Richard B Lipton; Vincent Martin; Vasilios Papademetriou; Wayne Rosamond; Antoinette MaassenVanDenBrink; Hassan Loutfi; K Michael Welch; Peter J Goadsby; Steven Hahn; Susan Hutchinson; David Matchar; Stephen Silberstein; Timothy R Smith; R Allan Purdy; Jane Saiers
Journal:  Headache       Date:  2004-05       Impact factor: 5.887

7.  A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.

Authors: 
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

Review 9.  Advances in the basic and clinical science of migraine.

Authors:  Andrew Charles
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

10.  Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.

Authors:  Lisa K Mannix; Vincent T Martin; Roger K Cady; Merle L Diamond; Shelly E Lener; Jonathan D White; Frederick J Derosier; Susan A McDonald
Journal:  Obstet Gynecol       Date:  2009-07       Impact factor: 7.661

View more
  27 in total

1.  Migraine Therapy: Current Approaches and New Horizons.

Authors:  Peter J Goadsby; Philip R Holland
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 2.  A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches.

Authors:  Jacquelin Peck; Ivan Urits; Justin Zeien; Shelby Hoebee; Mohammad Mousa; Hamed Alattar; Alan D Kaye; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2020-03-21

3.  The Inclusion of Tolfenamic Acid into Cyclodextrins Stimulated by Microenvironmental pH Modification as a Way to Increase the Anti-Migraine Effect.

Authors:  Anna Stasiłowicz; Ewa Tykarska; Natalia Rosiak; Kinga Sałat; Anna Furgała-Wojas; Tomasz Plech; Kornelia Lewandowska; Katarzyna Pikosz; Kamil Pawłowicz; Judyta Cielecka-Piontek
Journal:  J Pain Res       Date:  2021-04-14       Impact factor: 3.133

Review 4.  Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Oliver Clark; Areej Mahjoub; Nily Osman; Ann-Marie Surmava; Saber Jan; Ana Marissa Lagman-Bartolome
Journal:  Neurol Sci       Date:  2021-10-26       Impact factor: 3.307

5.  Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study.

Authors:  Sultan Tuna Akgol Gur; Elif Oral Ahiskalioglu; Muhammed Enes Aydin; Abdullah Osman Kocak; Pelin Aydin; Ali Ahiskalioglu
Journal:  Eur J Clin Pharmacol       Date:  2021-09-16       Impact factor: 2.953

6.  Protein kinase Cδ as a neuronal mechanism for headache in a chronic intermittent nitroglycerin model of migraine in mice.

Authors:  Ying He; Zuoxiao Shi; Yavnika Kashyap; Robert O Messing; Zaijie Jim Wang
Journal:  Pain       Date:  2021-10-01       Impact factor: 7.926

7.  Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation.

Authors:  Anroop B Nair; Jigar Shah; Shery Jacob; Bandar E Al-Dhubiab; Vimal Patel; Nagaraja Sreeharsha; Pottathil Shinu
Journal:  Pharmaceutics       Date:  2021-05-15       Impact factor: 6.321

Review 8.  Endocannabinoid System and Migraine Pain: An Update.

Authors:  Rosaria Greco; Chiara Demartini; Anna M Zanaboni; Daniele Piomelli; Cristina Tassorelli
Journal:  Front Neurosci       Date:  2018-03-19       Impact factor: 4.677

Review 9.  An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.

Authors:  Ivan Urits; Gavin Clark; Daniel An; Bredan Wesp; Rebecca Zhou; Ariunzaya Amgalan; Amnon A Berger; Hisham Kassem; Anh L Ngo; Alan D Kaye; Rachel J Kaye; Elyse M Cornett; Omar Viswanath
Journal:  Pain Ther       Date:  2020-03-28

10.  Pharmacokinetic Study of Frovatriptan Succinate Tablet After Single and Multiple Oral Doses in Chinese Healthy Subjects.

Authors:  Hongquan Zheng; Yan Xia; Shengjun Qu; Lin Fan; Jingjing Zhang; Zhixiang Ma; Yangsheng Chen; Hongwei Fan
Journal:  Drug Des Devel Ther       Date:  2021-07-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.